Tia L. Bush - 09 Sep 2025 Form 4 Insider Report for Centessa Pharmaceuticals plc (CNTA)

Role
Chief Technology & Quality Ofc
Signature
/s/ Raphael Deferiere, attorney-in-fact
Issuer symbol
CNTA
Transactions as of
09 Sep 2025
Net transactions value
-$611,756
Form type
4
Filing time
11 Sep 2025, 17:50:55 UTC
Previous filing
04 Feb 2025
Next filing
24 Sep 2025
SEC
View on sec.gov

Reporting Owners (1)

Name Relationship Address Signature Signature date CIK
Bush Tia L Chief Technology & Quality Ofc C/O CENTESSA PHARMACEUTICALS PLC, 3RD FL., 1 ASHLEY RD, ALTRINCHAM, CHESHIRE, UNITED KINGDOM /s/ Raphael Deferiere, attorney-in-fact 11 Sep 2025 0001863418

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction CNTA Ordinary Shares Options Exercise $198,584 +24,792 +20% $8.01 146,295 09 Sep 2025 Direct F1
transaction CNTA Ordinary Shares Sale $495,840 -24,792 -17% $20.00 121,503 09 Sep 2025 Direct F1, F2
transaction CNTA Ordinary Shares Options Exercise $235,500 +25,000 +21% $9.42 146,503 10 Sep 2025 Direct F1
transaction CNTA Ordinary Shares Sale $550,000 -25,000 -17% $22.00 121,503 10 Sep 2025 Direct F1, F2

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction CNTA Share Option (right to buy) Options Exercise $0 -24,792 -15% $0.000000 145,208 09 Sep 2025 Ordinary Shares 24,792 $8.01 Direct F1, F3
transaction CNTA Share Option (right to buy) Options Exercise $0 -25,000 -5% $0.000000 475,338 10 Sep 2025 Ordinary Shares 25,000 $9.42 Direct F1, F4
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Buy Plan / Sale Plan: These are also open market purchases/sales of shares, but in this case the transaction is part of a trading plan. Rule 10b5-1 allows insiders to setup a trading plan to buy/sell stocks over a certain period of time. Since the purchases/sales are predetermined, this protects the insiders from violating insider trading law.

Transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c).

Explanation of Responses:

Id Content
F1 The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share.
F2 The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on September 14, 2024.
F3 1/48th of the shares subject to such option shall vest and become exercisable in equal monthly installments with the first installment vesting on March 1, 2024.
F4 25% of the shares subject to such option shall vest and become exercisable on May 20, 2022 and the remaining 75% of the shares subject to such option shall vest and become exercisable in 36 monthly installments on the first day of each month thereafter.

Remarks:

Exhibit 24.2 - Substitute Power of Attorney